CVS Health Analyst Price Targets - Benzinga

CVS Health Corp

CVSNYSE

Trade with Public

Trade with Public

$96.76

2.853.03%

Last update: Sep 1, 2:00 PM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Dividends Compare Options Stock Report

CVS Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for CVS Health (CVS).

Price Target Range — 9 Quarters

Analyst Consensus — 20 Analysts

20Buy

Consensus RatingBuy# Analysts20Avg. Consensus PT$104Upside to Avg. PT+7.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 19, 2026	Argus Research	Steve Silver	PT Raise	Buy	$104→$114
Aug 12, 2026	JP Morgan	Lisa Gill	PT Raise	Overweight	$111→$118
Aug 6, 2026	UBS	Kevin Caliendo	PT Raise	Buy	$122→$126
Aug 6, 2026	Evercore ISI Group	Elizabeth Anderson	PT Cut	Outperform	$130→$125
Aug 6, 2026	Barclays	Andrew Mok	PT Raise	Overweight	$106→$108
Jul 24, 2026	UBS	Kevin Caliendo	PT Raise	Buy	$115→$122
Jul 14, 2026	Truist Securities	David Macdonald	PT Raise	Buy	$108→$118
Jul 13, 2026	Wells Fargo	Stephen Baxter	PT Raise	Overweight	$103→$123
Jul 9, 2026	RBC Capital	Ben Hendrix	PT Raise	Outperform	$107→$113
Jul 7, 2026	Cantor Fitzgerald	Sarah James	PT Raise	Overweight	$100→$110
Jun 23, 2026	B of A Securities	Allen Lutz	PT Raise	Buy	$100→$110
Jun 8, 2026	Mizuho	Ann Hynes	PT Raise	Outperform	$110→$115
Jun 4, 2026	Morgan Stanley	Erin Wright	PT Raise	Overweight	$106→$111
Jun 1, 2026	Truist Securities	David Macdonald	PT Raise	Buy	$102→$108
May 26, 2026	Barclays	Andrew Mok	PT Raise	Overweight	$101→$106
May 20, 2026	Mizuho	Ann Hynes	PT Raise	Outperform	$102→$110
May 14, 2026	Morgan Stanley	Erin Wright	PT Raise	Overweight	$93→$106
May 13, 2026	Bernstein	Lance Wilkes	PT Raise	Outperform	$94→$106
May 12, 2026	JP Morgan	Lisa Gill	PT Raise	Overweight	$101→$111
May 11, 2026	TD Cowen	Charles Rhyee	PT Raise	Buy	$105→$110

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Argus Research Maintains Buy on CVS Health, Raises Price Target to $114

Argus Research analyst Steve Silver maintains CVS Health (NYSE:CVS) with a Buy and raises the price target from $104 to $114.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on CVS Health, Raises Price Target to $118

JP Morgan analyst Lisa Gill maintains CVS Health (NYSE:CVS) with a Overweight and raises the price target from $111 to $118.

Benzinga Newsdesk

PRO
UBS Maintains Buy on CVS Health, Raises Price Target to $126

UBS analyst Kevin Caliendo maintains CVS Health (NYSE:CVS) with a Buy and raises the price target from $122 to $126.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on CVS Health, Lowers Price Target to $125

Evercore ISI Group analyst Elizabeth Anderson maintains CVS Health (NYSE:CVS) with a Outperform and lowers the price target from $130 to $125.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on CVS Health, Raises Price Target to $108

Barclays analyst Andrew Mok maintains CVS Health (NYSE:CVS) with a Overweight and raises the price target from $106 to $108.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on CVS Health, Raises Price Target to $118

Truist Securities analyst David Macdonald maintains CVS Health (NYSE:CVS) with a Buy and raises the price target from $108 to $118.

Benzinga Newsdesk